More than 96 per cent of children who took part in the UAE's Sinopharm vaccine trial developed antibodies to fight COVID-19.
Also, no major side effects were reported in the 900 young volunteers, aged 3-17.
The details were revealed during the government's latest media briefing on Tuesday.
Officials said 29.7 per cent had pain at the injection site, 8 per cent had a headache, while 3.7 per cent had a fever.
Earlier this month, the UAE gave its approval for using Sinopharm vaccine in children aged 3-17.
During the latest briefing, Dr. Noura Al Ghaithi, Acting Chief Executive Officer of Ambulatory Healthcare Services at SEHA, also reiterated the benefits of getting vaccinated.
From January 1- July 23, eight out of 10 people who were hospitalised due to COVID-19 were found to be unvaccinated, while nine out of 10 unvaccinated patients were sent to intensive care.
RTA installs 595 bus shelters in key areas across Dubai
H.H. Sheikh Mohammed meets with African business, philanthropic leaders
Zayed bin Hamdan meets Azerbaijan’s Minister of Economy
UAE joins seven nations in rejecting Israel's one-way Gaza exit plan
Woman detained after sword stunt during Eid Al Etihad goes viral
